There are 2867 resources available
365P - Prognostic value of Lynch syndrome, BRAFV600E and RAS mutation status in dMMR/MSI-H metastatic colorectal cancer in a pooled analysis of the national Dutch and French cohorts
Presenter: Koen Zwart
Session: Poster session 07
366P - The PLK1 inhibitor onvansertib overcomes irinotecan resistance in RAS-mutated (mRAS) metastatic colorectal cancer (mCRC) in vivo and in patients (pts)
Presenter: Scott Kopetz
Session: Poster session 07
367P - Prospective evaluation of emergent RAS and BRAF mutations in pre-treated metastatic colorectal cancer patients candidate to anti-EGFR re-treatment: Preliminary findings from the PARERE study
Presenter: Marco Germani
Session: Poster session 07
368P - Characteristics and survival of metastatic colorectal cancer patients receiving local treatment with deficient mismatch repair versus proficient mismatch repair
Presenter: Jeanine Roodhart
Session: Poster session 07
370P - Trastuzumab-emtansine (T-DM1) in HER2-amplified metastatic colorectal cancer patients progressing to trastuzumab-lapatinib: The HERACLES RESCUE phase II trial
Presenter: Andrea Sartore Bianchi
Session: Poster session 07
371P - A phase Ia/b, open-label, multicentre study of the TRAILR2 agonist BI 905711 in patients (pts) with advanced gastrointestinal (GI) cancers
Presenter: James Harding
Session: Poster session 07
372P - Microsatellite instability testing practices in colorectal cancer patients, in Europe and Asia
Presenter: Kriti Jindal
Session: Poster session 08
373P - The role of concomitant RAS and BRAF mutations in influencing clinical outcome during BRAF-targeted treatment for metastatic colorectal cancer
Presenter: Andrea Pretta
Session: Poster session 08
374P - Influence of sex on safety and efficacy in BRAF-V600E mutated metastatic colorectal cancer (mCRC) treated with encorafenib-cetuximab +/-binimetinib (E-C+/-B)
Presenter: Francisco Javier Ros Montana
Session: Poster session 08